Dr. JB McIntyre is the lead molecular scientist at the Cancer Translational Research Core laboratory at the Arthur Child Comprehensive Cancer Centre. He obtained his BSc from the University of New Brunswick in biochemistry and PhD in molecular biology from the University of Calgary. Dr. McIntyre’s research focuses on cancer biomarker discovery and validation, with particular interest in the investigation and clinical implementation of prognostic and predictive genomic biomarkers that can inform clinicians and improve patient outcomes. To that end, Dr. McIntyre actively collaborates with researchers and clinician scientists to bridge knowledge gaps that can drive the development of novel molecular assays used in the screening, diagnosis and treatment of cancer by employing genomics-based approaches in combination with proteomics, metabolomics and immunotherapies to redefine standard of care for cancer patients.
McIntyre, John
Fundamental Research
Research Assistant Professor
Biography
Area of Focus
- Translational Research
- Genomics
- Precision Oncology
- Molecular Biology
Summary of Research
Key Publications:
- Papadimitriou M, Ahn S, Diamond B, Lee H, McIntyre JB, Truger M, Durante M, Ziccheddu B, Osz K, Landgren O, Rasche L, Bahlis NJ, Neri P, Maura F. Timing genomic antigen loss in multiple myeloma treated with T cell-redirecting immunotherapies. Blood Cancer Discov. 2025 Nov 3;6(6):572-579
- Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, Landgren O, Walter W, Meggendorfer M, Haferlach C, Haferlach T, Einsele H, Kortüm MK, Knop S, Alberge JB, Rosenwald A, Keats JJ, Rasche L, Maura F, Neri P, Bahlis NJ. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023 Sep;29(9):2295-2306
- Eszlinger M, Khalil M, Gillmor AH, Huang H, Stewardson P, McIntyre JB, Morrissy S, Paschke R. Histology-based molecular profiling improves mutation detection for advanced thyroid cancer. Genes Chromosomes Cancer. 2021 Aug;60(8):531-545
- Martell K, McIntyre JB, Kornaga EN, Chan AMY, Phan T, Kobel M, Enwere EK, Dean ML, Ghatage P, Lees-Miller SP, Doll CM. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. Gynecol Oncol. 2020 Sep;158(3):776-784
- McIntyre JB, Wu J, Phan T, Craighead PS, Lees-Miller S, Kobel M, Ghatage P, Magliocco AM, and CM Doll. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol 2013 Mar;128 (3):409-14
Area Of Focus
- Translational Research
- Genomics
- Precision Oncology
- Molecular Biology
Summary Of Research
Key Publications:
- Papadimitriou M, Ahn S, Diamond B, Lee H, McIntyre JB, Truger M, Durante M, Ziccheddu B, Osz K, Landgren O, Rasche L, Bahlis NJ, Neri P, Maura F. Timing genomic antigen loss in multiple myeloma treated with T cell-redirecting immunotherapies. Blood Cancer Discov. 2025 Nov 3;6(6):572-579
- Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, Landgren O, Walter W, Meggendorfer M, Haferlach C, Haferlach T, Einsele H, Kortüm MK, Knop S, Alberge JB, Rosenwald A, Keats JJ, Rasche L, Maura F, Neri P, Bahlis NJ. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023 Sep;29(9):2295-2306
- Eszlinger M, Khalil M, Gillmor AH, Huang H, Stewardson P, McIntyre JB, Morrissy S, Paschke R. Histology-based molecular profiling improves mutation detection for advanced thyroid cancer. Genes Chromosomes Cancer. 2021 Aug;60(8):531-545
- Martell K, McIntyre JB, Kornaga EN, Chan AMY, Phan T, Kobel M, Enwere EK, Dean ML, Ghatage P, Lees-Miller SP, Doll CM. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. Gynecol Oncol. 2020 Sep;158(3):776-784
- McIntyre JB, Wu J, Phan T, Craighead PS, Lees-Miller S, Kobel M, Ghatage P, Magliocco AM, and CM Doll. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol 2013 Mar;128 (3):409-14